This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1159/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q82986692
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel scientific article published on 27 March 2006 наукова стаття, опублікована в березні 2006 artículu científicu espublizáu en marzu de 2006
p:P577
wds:Q82986692-44F1606F-C4EA-4F44-A2D9-CA7575197225
wdt:P577
2006-03-27T00:00:00Z
p:P2093
wds:Q82986692-36F0F22E-2975-450E-B533-C4B00F9DE7DD wds:Q82986692-344310A7-B59E-4159-B7F4-B63A0B9A4FDE wds:Q82986692-7BAB47B4-6CB6-4297-B10A-50660B5F733D
wdt:P2093
Tsutomu Izawa Yasuhiro Nakano Nobuyuki Yanagawa
rdfs:label
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer
skos:prefLabel
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer
schema:name
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer
p:P50
wds:Q82986692-750442BC-AA0F-4A2B-B122-B7168E850199 wds:Q82986692-76ABD1C7-A490-4587-B0C1-AD93666F07A9 wds:Q82986692-C30394CB-4BEC-4EAF-88AB-E571A767C81C wds:Q82986692-A1BD6EB2-7691-4036-ACFF-A53EC59586EE wds:Q82986692-276F5BEF-4C14-459B-8678-E1AC72B64CB9 wds:Q82986692-242752AD-71FB-4922-9D61-BAFAD496B4B8 wds:Q82986692-2C625862-D1BA-4C14-AE24-E503C5274752 wds:Q82986692-27706FE4-A4E4-47EB-8871-D5945B7F7D0F
wdt:P50
wd:Q114407829 wd:Q89800338 wd:Q59678803 wd:Q68147150 wd:Q114407834 wd:Q114407826 wd:Q114407827 wd:Q114407825
p:P1476
wds:Q82986692-F49C5103-E0C9-4C9C-ACDE-0ED8A1F6BD6A
wdt:P1476
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer
p:P304
wds:Q82986692-D8289F0B-1317-48B5-8DEE-BDDA504F37DA
wdt:P304
98-102
p:P31
wds:Q82986692-2CE89681-420A-42B4-81B0-236A9B5388F6
wdt:P31
wd:Q13442814
p:P921
wds:Q82986692-2FD8FABC-56CB-4186-BD76-7BA28C976256
wdt:P921
wd:Q212961
p:P698
wds:Q82986692-9F353585-7851-4DD1-B5C3-CF205A6BD8ED
wdtn:P698
n12:16567941
wdt:P698
16567941
p:P1433
wds:Q82986692-7979CCA8-37BA-4E15-9BFB-71E5C99E8F16
wdt:P1433
wd:Q2440355
p:P433
wds:Q82986692-1F2DFD1E-8E72-43B2-89CD-B0448A17EDA9
p:P478
wds:Q82986692-765D4722-C82B-4FCB-8710-427AA8C347F6
wdt:P433
2
wdt:P478
52
p:P356
wds:Q82986692-5283E675-3535-43E9-859C-E7187D5D03E1
wdtn:P356
n11:000092372
wdt:P356
10.1159/000092372